The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Various | |
| 2 | V10 | Therapeutic radiopharmaceuticals | |
| 3 | V10X | Other therapeutic radiopharmaceuticals | |
| 4 | V10XA | Iodine (131I) compounds |
| Code | Title | |
|---|---|---|
| V10XA01 | Sodium iodide (131I) | |
| V10XA02 | Iobenguane (131I) | |
| V10XA03 | ||
| V10XA53 | Tositumomab/iodine (131I) tositumomab |
| Active Ingredient | Description | |
|---|---|---|
| Iobenguane ¹³¹I |
Iobenguane is similar in structure to the neurotransmitter norepinephrine (NE) and is subject to the same uptake and accumulation pathways as NE. Pheochromocytoma and paraganglioma (PPGL) are tumors of neural crest origin that express high levels of the NE transporter on their cell surfaces. Following intravenous administration, iobenguane ¹³¹I is taken up and accumulates within pheochromocytoma and paraganglioma cells, and radiation resulting from radioactive decay of ¹³¹I causes cell death and tumor necrosis. |
|
| Sodium iodide ¹³¹I |
Iodide is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Sodium iodide ¹³¹I is used for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. The beta emission of I 131 is responsible for the therapeutic effect. |
